Base year for macv contract generates macv IGG2
Ended Definitive Contract Awarded Last action
- Contract number
- W81XWH21C0121
- Awardee
-
Mapp Biopharmaceutical, Inc. UEI M9V9QTHR1H28
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $601,142
Award facts
- Opportunity
-
- W81XWH21R0089 Solicitation number
- Contract value 50% obligated
-
- $767,803.19 Current, with exercised options
- $1,192,803.19 Potential, with all options
- Completion date 100% complete
-
- Current, with exercised options
- Potential, with all options
- Contracting staff
- NAICS code
- 541380 Testing Laboratories and Services
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Basic Research
- Pricing
- Firm Fixed Price
- Place of performance
- Frederick, MD 21702, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | -$9,697 | |
| Funding Only Action | -$89,578 | |
| Exercise an Option | $297,500 | |
| Other Administrative Action | $0 | |
| Change Order | $0 | |
| Funding Only Action | $88,802 | |
| Original award | $314,115 |
About this award
This is a Definitive Contract awarded to Mapp Biopharmaceutical, Inc., a biotechnology company based in San Diego, California, by the Defense Health Agency, a component of the U.S. Department of Defense. The contract has a ceiling value of $1,192,803.19 and is for the BASE YEAR of the MACV Contract, which generates MACV IGG2. The contract is a Firm Fixed Price arrangement with a period of performance through March 1, 2025. There was no set-aside designation for this award. Mapp Biopharmaceutical has received numerous other federal contract and grant awards from agencies such as the Department of Health and Human Services and the Defense Threat Reduction Agency to support its research and development of antibody-based therapeutics and medical countermeasures against infectious diseases, including Ebola, Marburg, and botulinum neurotoxin. This contract further demonstrates the company's role as a key partner in the U.S. government's efforts to prepare for and respond to public health emergencies and national security threats.
Quick answers
Who was awarded contract W81XWH21C0121?
W81XWH21C0121 was awarded to Mapp Biopharmaceutical, Inc. by Defense Health Agency (Department of Defense) on September 30, 2021.
How much is contract W81XWH21C0121 worth?
The government has obligated $601,142 on W81XWH21C0121. Its current value, with exercised options, is $767,803. Its potential value, with all options, is $1,192,803.
Was contract W81XWH21C0121 competed?
The extent of competition for W81XWH21C0121 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award